The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Nataliya Andreychuk, CEO of Viseven, about her personal battle with breast cancer.
Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20th-24th October, which was back at full capac
In order for cell therapies to scale effectively, the industry is clamouring for standardisation around things like manufacturing and treatment administration.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.